“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors”

RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021

David J. Elzi, William E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and Vivienne I. Rebel
The presentation explains bioAffinity Technologies’ discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue. In particular, bioAffinity’s research shows how the Company has designed and used siRNAs to kill multiple cancers at the cellular level including prostate, lung, breast, brain and skin cancers without harm to normal cells.